| 摘要 |
<p>The invention provides methods of diagnosing whether a subject has, or is at risk for developing, lung cancer, comprising measuring the level of at least one miR gene product in a test sample from said subject, wherein an alteration in the level of the miR gene products in the test sample, relative to the level of corresponding miR gene products in a control sample, is indicative of the subject either having, or being at risk for developing, lung cancer.</p><p>The invention also provides methods of diagnosing whether a subject has, or is at risk for developing, lung cancer, comprising:
reverse transcribing RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides;
hybridizing the target oligodeoxynucleotides to a microarray comprising miRNA-specific probe oligonucleotides to provide a hybridization profile for the test sample; and
comparing the test sample hybridization profile to a hybridization profile generated from a control sample,
wherein an alteration in the signal of at least one miRNA is indicative of the subject either having, or being at risk for developing, lung cancer.</p><p>The at least one miR gene product is selected from the group consisting of miR-21, miR-191, miR-155, miR-210, miR-126* and miR-224.
</p> |
